Overview

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Status:
Recruiting

Trial end date:
2022-01-27

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Mirikizumab